- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04306224
En undersøgelse af IMC-002 i forsøgspersoner med metastaserende eller lokalt avancerede solide tumorer og recidiverende eller refraktære lymfomer
En første-i-menneskelig, åben-label, multipel-stigende dosis-undersøgelse til undersøgelse af sikkerhed, tolerabilitet, farmakokinetik, farmakodynamik og klinisk aktivitet af IMC-002 hos forsøgspersoner med metastatiske eller lokalt avancerede solide tumorer og recidiverende eller refraktære lymfomer
This is the first-in-human, Phase I, open-label, multiple-ascending dose study to investigate the safety, tolerability, PK, PharmDyn, and clinical activity of IMC-002 in subjects with metastatic or locally advanced solid tumors and relapsed or refractory lymphomas.
Male or female subjects 18 years and older with metastatic or locally advanced solid tumors and relapsed or refractory lymphomas will be included in the study if they meet all the inclusion criteria and none of the exclusion criteria.
The study will consist of 2 parts:
Part 1: Dose Escalation Part 2: Expansion Cohorts
Studieoversigt
Detaljeret beskrivelse
Part 1: Dose Escalation
Part 2: Expansion Cohort The study may be amended in the future to include expansion cohorts in selected tumor types to further evaluate extended safety of IMC-002 at recommended Phase 2 dose in that tumor type. Sample size in the Dose Expansion part will be determined when the study is amended to include the expansion cohorts.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Washington University School of Medicine - Siteman Cancer Center
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- The University of Texas MD Anderson Cancer Center
-
San Antonio, Texas, Forenede Stater, 78229
- NEXT Oncology
-
-
-
-
-
Seoul, Sydkorea, 03080
- Seoul National University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria
Subjects are eligible to be included in the study only if all of the following criteria apply:
- Signed informed consent form (ICF)
- Adult (18 years or older)
- Histologically or cytologically proven metastatic or locally advanced solid tumors and relapsed or refractory lymphomas, for which no standard therapy known to prolong survival exists or have relapsed/refractory/PD following the last line of treatment
- Solid tumors must be measurable with at least 1 unidimensional measurable lesion by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Lymphomas must have at least 1 measurable lesion according to the Lugano criteria with the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) modification
- Availability of tumor archival material or fresh biopsies for measurement of CD47
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at Screening and an estimated life expectancy of at least 3 months
- Adequate hematologic function, hepatic function, and renal function
Exclusion Criteria
Subjects are excluded from the study if any of the following criteria apply:
- Treatment with nonpermitted drugs (within 28 days before Day 1).
- Prior treatment with a CD47 or SIRPα targeting agent
- Concurrent anticancer treatments within 28 days before Day 1/first study treatment administration
- Major surgery or significant traumatic injury within 6 weeks prior to Screening or planned major surgery during the study period
- Previous malignant disease other than the target malignancy for this study, except adequately treated Stage I or II cancers from which the subject is currently in complete remission per the Investigator's clinical judgment
- Primary central nervous system (CNS) disease or leptomeningeal disease; known CNS metastases unless treated
- Comorbidities/medical history of any significant diseases that in the judgment of the Investigator would make the subject inappropriate for this study
- Active infection requiring systemic therapy within 14 days before Day 1
- Persisting toxicities Grade > 1 NCI-CTCAE Version 5.0 related to prior anticancer treatment
- Pregnant or lactating
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: IMC-002
Dose escalation will follow the traditional 3+3 design. |
IMC-002 blocks the interaction between CD47 and SIRPα. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Forekomst af dosisbegrænsende toksicitet (DLT)
Tidsramme: I 28 dage
|
I 28 dage
|
|
Hyppighed og sværhedsgrad af bivirkninger (AE'er)
Tidsramme: 2 år
|
2 år
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: HEUNG TAE KIM, ImmuneOncia Therapeutics Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IMC-002-101
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .